Predicting gout flares in people starting allopurinol using the start‐low go‐slow dose escalation strategy

Lisa K Stamp,Anne Horne,Borislav Mihov,Jill Drake,Janine Haslett,Peter Chapman,Christopher Frampton,Nicola Dalbeth

DOI: https://doi.org/10.1002/acr.25376

2024-05-22

Arthritis Care & Research

Abstract:Objective To determine predictors of gout flare when commencing allopurinol using the "start‐low go‐slow" dose escalation strategy. Methods A post hoc analysis of a 12 month double‐blind placebo‐controlled non‐inferiority trial with participants randomised 1:1 to colchicine 0.5mg daily or placebo for the first six months was undertaken. Multivariate logistic regression models were used to identify independent predictors of gout flares in the first and last six months of the trial. Results Multivariable analysis revealed a significant association between risk of a gout flare in the first six months and flare in the month prior to starting allopurinol (odds ratio (OR) (95% confidence interval (CI)) 2.65 (1.36‐5.17)) and allopurinol 100mg starting dose (OR (95% CI) 3.21 (1.41‐7.27)). The predictors of any gout flares in the last six months of the trial, after stopping colchicine or placebo, were having received colchicine (OR (95% CI) 2.95 (1.48‐5.86)), at least one flare in the month prior to stopping study drug (OR (95% CI) 5.39 (2.21‐13.15)), and serum urate ≥0.36mmol/L at month 6 (OR (95% CI) 2.85 (1.14‐7.12)). Conclusions Anti‐inflammatory prophylaxis when starting allopurinol using the "start‐low go‐slow" dose escalation strategy may be best targeted at those who have had a gout flare in the month prior to starting allopurinol and are commencing allopurinol 100mg daily. For those with ongoing gout flares during the first six months of starting allopurinol who have not yet achieved serum urate target, a longer period of prophylaxis may be required.

rheumatology